Cannabis Law and Access in Costa Rica

Costa Rica's cannabis framework is not what most people assume

Forty-eight countries have moved some form of cannabis legislation in the past decade. Costa Rica is not one of the bold movers , but it is one of the more interesting ones to watch, precisely because its legal position is genuinely ambiguous rather than neatly resolved. I've been tracking this particular jurisdiction for a while now, partly because Central American regulatory shifts tend to get underreported in English-language coverage, and partly because the gap between what the law says and what the law does is unusually wide here.

For Australian readers: nothing in this article applies to Australian law. Cannabis scheduling, access pathways, and prescribing frameworks in Australia sit under the Therapeutic Goods Administration and the Poisons Standard , a completely separate system. If you're looking for how Schedule 8 controlled drug status works here, or how the Special Access Scheme operates, those are different articles entirely. What follows is a factual account of Costa Rican law for educational context.

The legal baseline: recreational cannabis remains prohibited

Recreational cannabis is illegal in Costa Rica. Full stop. The relevant instrument is the Ley General de Salud (General Health Law) and its associated regulations, alongside the Ley sobre Estupefacientes, Sustancias Psicotrópicas, Drogas de Uso No Autorizado y Actividades Conexas , Law 8204; which governs narcotics and controlled substances. Under Law 8204, the possession, sale, trafficking, and cultivation of cannabis for non-authorised purposes carries criminal penalties.

Possession of small quantities for personal use sits in a legal grey zone. Costa Rican courts have sometimes applied a principle of proportionality, distinguishing between users and traffickers, but this is not codified as decriminalisation in the way, say, Portugal's Law 30/2000 is. There is no statutory threshold amount below which possession becomes automatically non-criminal. In practice, enforcement varies considerably depending on location and circumstance, but relying on inconsistent enforcement is not a legal strategy.

Industrial hemp: a separate regulatory track

Hemp is where the picture shifts. In 2019, Costa Rica passed Executive Decree 41546-S-COMEX, authorising the cultivation, processing, and commercialisation of industrial hemp, defined as Cannabis sativa L. with a tetrahydrocannabinol content at or below 1% by dry weight. That threshold is notably more permissive than many jurisdictions (the EU uses 0.3%, as does Australia for most industrial purposes).

The decree created a licensing regime administered jointly by the Ministry of Health (Ministerio de Salud) and the Ministry of Foreign Trade (COMEX). Licences cover seed importation, cultivation, and processing into hemp-derived products. Exports of hemp-derived extracts, including cannabidiol fractions, were explicitly contemplated; this was partly a commercial play, positioning Costa Rica to supply international cosmetic and extract markets.

Practically speaking, the regulatory infrastructure to fully implement the decree took time to build. Early applicants found the inter-ministerial approval process slow. But the framework is real and operative, and a small number of licensed operators have worked under it.

Medicinal cannabis: the 2022 legislation

The more significant development came in May 2022, when Costa Rica's Legislative Assembly passed Law 10113, the Ley para la Investigación, Regulación y Control del Cannabis Medicinal y el Cáñamo Industrial (Law for the Research, Regulation and Control of Medicinal Cannabis and Industrial Hemp). This consolidated and expanded the 2019 hemp decree into a proper statutory framework.

Law 10113 creates a legal basis for:

• Cultivation of cannabis for medicinal purposes under licence
• Processing and manufacture of medicinal cannabis products
• Domestic sale of authorised medicinal cannabis products through regulated channels
• Export of medicinal cannabis products
• Scientific research involving cannabis

The Ministry of Health retains central regulatory authority, with COMEX involved for trade-related matters. A new national registry for medicinal cannabis operators, cultivators, processors, distributors; was established under the law. The Instituto Costarricense sobre Drogas (ICD), which had historically been the primary drug-control agency, has a coordination role alongside the Health Ministry.

Importantly, Law 10113 does not legalise recreational use. The distinction between medicinal and recreational access is maintained, and the law is explicit that recreational cannabis remains outside the authorised framework.

Patient access in practice

This is where I'd urge some caution in how the law gets characterised. Passing a medicinal cannabis law and having functional patient access are not the same thing. The implementing regulations under Law 10113 were still being developed and refined through 2023 and into 2024. Authorised medicinal products need to be registered, prescribing frameworks need to be operational, and pharmacy dispensing pathways need to exist.

From what I can piece together through official Costa Rican Health Ministry communications and regional legal analyses, access for patients is nascent rather than mature. The legal right exists; the practical infrastructure is still catching up. This is not unusual, Australia went through a similar gap between the 2016 legislative reforms and having accessible, affordable product on the ground years later.

For context, Costa Rica's Caja Costarricense de Seguro Social (CCSS), the national social security health system, has not broadly integrated medicinal cannabis into its formulary. Private medical pathways are the realistic route for patients at this stage.

Cannabis chemistry in the regulated context

One thing Law 10113 does engage with, at least in principle, is the distinction between different cannabinoid profiles. Authorised products are expected to have defined and tested compositions. For readers curious about why this matters chemically: the profile of any cannabis-derived extract, whether it's a full-spectrum preparation containing multiple cannabinoids and terpenes, a broad-spectrum product, or a cannabinoid isolate; affects how it is classified and regulated. THC content is the primary regulatory trigger in most jurisdictions, including Costa Rica, because of its psychoactive properties mediated through CB1 receptors in the central nervous system.

Honestly, the chemistry sections of regulatory frameworks fascinate me, probably an occupational hazard. I spent a Saturday morning a few weeks back cross-referencing the THC threshold definitions across six jurisdictions while Trevor (my sourdough starter, long story) quietly did his thing on the bench. The definitional inconsistency across legal systems is remarkable. Costa Rica's 1% hemp threshold, the EU's 0.3%, Australia's 1% limit under the industrial hemp exemption in the Narcotic Drugs Act, same plant, genuinely different regulatory constructions.

What about CBD specifically?

Under the hemp decree and Law 10113, hemp-derived CBD products sit within the authorised framework provided they come from licensed sources and meet the THC threshold. Cosmetic-grade CBD products derived from licensed hemp have circulated in the Costa Rican market. Medicinal CBD products for internal use require the full medicinal licensing pathway.

This mirrors a split seen in many jurisdictions; cosmetic hemp extracts in one regulatory lane, medicinal products in another, with the latter carrying significantly more compliance burden. Australian readers will recognise a similar structure: low-dose CBD was down-scheduled to Schedule 3 (pharmacist-only) in 2021 under specific conditions, whilst higher-dose preparations remain Schedule 4 prescription-only or Schedule 8 where THC is present above threshold.

The enforcement reality and regional context

Costa Rica sits in a region where drug-trafficking enforcement is a genuine public safety concern, and Law 8204's serious penalties for trafficking are actively enforced. The country has historically positioned itself as a rule-of-law jurisdiction by regional standards, which makes the incremental, licensing-based approach to cannabis reform fairly consistent with its broader governance style.

Neighbouring countries vary widely. Uruguay legalised recreational cannabis nationally in 2013 (the first country in the world to do so under a state-control model). Several others in the region remain strictly prohibitionist. Costa Rica sits somewhere in the middle, medicinal and hemp reform proceeding deliberately, recreational use remaining prohibited.

In my view, the 1% THC threshold for hemp is actually a reasonable call given where the science sits on incidental psychoactive exposure from hemp products. The risk of the threshold being misused to market borderline products is real, but an overly restrictive 0.2% threshold would have likely strangled the emerging domestic industry before it got started. Whether the regulatory capacity exists to enforce even 1% consistently is a separate question, and probably the more important one.

A note for Australian readers

If you've arrived here researching cannabis law because you're an Australian patient, carer, or clinician, please note: Australian access to medicinal cannabis is governed entirely by the TGA, the Poisons Standard, and the Narcotic Drugs Act 1967. The relevant pathways here are the Special Access Scheme and the Authorised Prescriber pathway. What applies in San José does not apply in Sydney, Canberra, or anywhere else in Australia. Separate jurisdictions, separate frameworks, no overlap in access law.

Sources

• Ley 10113; Ley para la Investigación, Regulación y Control del Cannabis Medicinal y el Cáñamo Industrial, Procuraduría General de la República de Costa Rica
• Narcotic Drugs Technical Reports, International Narcotics Control Board (INCB)
• Accessing cannabis products; Therapeutic Goods Administration (Australia)
• Cannabis, United Nations Office on Drugs and Crime (UNODC)

, Marcus Hale, Regulatory researcher, TGA & access law